REGENXBIO Inc.
RGNXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. At a $534.2M market cap, REGENXBIO Inc. ranks as a small-cap company within healthcare. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Market Cap
$534.2M
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-3.84
EPS (TTM)
$-5.60
EPS (Fwd)
$-2.57
ROE
-196.4%
ROA
-38.5%
Cash
$150.5M
Total Debt
$248.4M
Free CF
-$139.0M
52W Change
21.2%
Annual Financials
Cash vs Debt
On the balance sheet, RGNX has $150.5M in cash with $248.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$139.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -196.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $112.7M to $170.4M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RGNX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.